title: [Clinical effectiveness and safety of citalopram in patients with depression after myocardial infarction].
abstract: Citalopram (20 mg/day for 42 days) was given to 20 patients (mean age 54.4+/-2.5 years) with depression after myocardial infarction. This was associated with substantial antidepressive effect (50% and more lowering of the total score of the Beck depression questionnaire) in 89% of patients, reduction of number and severity of somatic complaints, and improvement of parameters of quality of life. Citalopram did not affect blood pressure and according to Holter ECG monitoring data produced no arrhythmogenic or proischemic effects. Overall tolerability of citalopram was good however 21% of patients experienced slight drowsiness, dizziness or sweating.
authors.forename: G V
authors.initials: GV
authors.lastname: Pogosova
authors.forename: N I
authors.initials: NI
authors.lastname: Zhidko
authors.forename: T G
authors.initials: TG
authors.lastname: Mikheeva
authors.forename: I Kh
authors.initials: IKh
authors.lastname: Baĭchorov
mesh_terms: D000328:Adult; D000368:Aged; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D039721:Diagnostic and Statistical Manual of Mental Disorders; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000523:psychology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors